Advertisement

Obesity pp 227-241 | Cite as

Obesity, Hypertension, and Dyslipidemia

  • Vasilios KotsisEmail author
  • Christina Antza
  • Giannis Doundoulakis
  • Stella Stabouli
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Hypertension and dyslipidemia are closely related with obesity. Obesity releases nonesterified fatty acids into the circulation, increasing fasting plasma triglycerides, reducing high-density lipoprotein cholesterol, and inducing a shift to a proatherogenic composition (small, dense) of low-density lipoproteins. Obesity activates the sympathetic nervous system, increases sodium and water reabsorption, and increases the production of angiotensin II factors that determine hypertension shift in obese people.

Keywords

Obesity Hypertension 

Abbreviations

24 h ABPM

24 hour ambulatory blood pressure monitoring

Ang

Angiotensin; RAS: Rennin–Ang system

BMI

Body Mass Index

BP

Blood pressure

FFAs

Free fatty acids

HDL

High-density lipoprotein

IDL

Intermediate density lipoproteins

LDL

Low-density lipoprotein

MAG

Monoacylglycerol

MetS

Metabolic syndrome

NAFLD

Non-alcoholic fatty liver disease

PCSK9

Proprotein convertase subtilisin/kexin type 9

PLs

Phospholipids

SNS

Sympathetic nervous system

TAG

Triacylglycerol

TG

Triglycerides

VLDL

Very low density lipoproteins

References

  1. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997;10(10 Pt 1):1171–4.PubMedCrossRefGoogle Scholar
  2. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992;19(6 Pt 2):621–7.PubMedCrossRefGoogle Scholar
  3. Baik I, Ascherio A, Rimm EB, Giovannucci E, Spiegelman D, Stampfer MJ, et al. Adiposity and mortality in men. Am J Epidemiol. 2000;152(3):264–71.PubMedCrossRefGoogle Scholar
  4. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, et al. Screening for obstructive sleep apnea in adults: US preventive services task force recommendation statement. JAMA. 2017;317(4):407–14.PubMedCrossRefGoogle Scholar
  5. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–10.PubMedCrossRefGoogle Scholar
  6. Byrne CD, Brindle NP, Wang TW, Hales CN. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem J. 1991;280(Pt 1):99–104.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79(1):1–6.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.PubMedCrossRefGoogle Scholar
  9. Chen CH, Wang PH, Liu BH, Hsu HH, Mersmann HJ, Ding ST. Serum amyloid a protein regulates the expression of porcine genes related to lipid metabolism. J Nutr. 2008;138(4):674–9.PubMedCrossRefGoogle Scholar
  10. Clemente-Postigo M, Queipo-Ortuno MI, Fernandez-Garcia D, Gomez-Huelgas R, Tinahones FJ, Cardona F. Adipose tissue gene expression of factors related to lipid processing in obesity. PLoS One. 2011;6(9):e24783.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes. 2002;51(2):439–42.PubMedCrossRefGoogle Scholar
  12. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, et al. Niemann-pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586–92.PubMedCrossRefGoogle Scholar
  13. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med. 1993;153(9):1093–103.PubMedCrossRefGoogle Scholar
  14. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch Intern Med. 1994;154(4):401–10.PubMedCrossRefGoogle Scholar
  15. Dwyer TM, Bigler SA, Moore NA, Carroll JF, Hall JE. The altered structure of renal papillary outflow tracts in obesity. Ultrastruct Pathol. 2000;24(4):251–7.PubMedCrossRefGoogle Scholar
  16. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am. 2011;95(5):893–902.PubMedCrossRefGoogle Scholar
  17. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc. 2001;60(3):375–80.PubMedCrossRefGoogle Scholar
  18. Gutierrez DA, Puglisi MJ, Hasty AH. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep. 2009;9(1):26–32.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int. 1993;43(6):1402–17.PubMedCrossRefGoogle Scholar
  20. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10(5 Pt 2):49s–55s.PubMedCrossRefGoogle Scholar
  21. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res. 2000;33(6):605–18.PubMedCrossRefGoogle Scholar
  22. Hardardottir I, Moser AH, Memon R, Grunfeld C, Feingold KR. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 1994;13(3):161–6.PubMedGoogle Scholar
  23. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 2008;93(8):3215–21.PubMedCrossRefGoogle Scholar
  24. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009;296(6):E1183–94.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002;112(4):275–80.PubMedCrossRefGoogle Scholar
  26. Kalia HS, Gaglio PJ. The prevalence and Pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis. 2016;20(2):215–24.PubMedCrossRefGoogle Scholar
  27. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–509.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Klop B, Wouter Jukema J, Rabelink TJ, Castro CM. A physician’s guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Panminerva Med. 2012;54(2):91–103.PubMedGoogle Scholar
  29. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Forum Nutr. 2013;5(4):1218–40.Google Scholar
  30. Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45(4):602–7.PubMedCrossRefGoogle Scholar
  31. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33(5):386–93.PubMedCrossRefGoogle Scholar
  32. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–24.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens. 1989;2(3 Pt 2):125s–32s.PubMedCrossRefGoogle Scholar
  34. Lo JC, Chandra M, Sinaiko A, Daniels SR, Prineas RJ, Maring B, et al. Severe obesity in children: prevalence, persistence and relation to hypertension. Int J Pediatr Endocrinol. 2014;2014(1):3.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Lundberg JM, Pernow J, Franco-Cereceda A, Rudehill A. Effects of antihypertensive drugs on sympathetic vascular control in relation to neuropeptide Y. J Cardiovasc Pharmacol. 1987;10(Suppl 12):S51–68.PubMedGoogle Scholar
  36. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMedCrossRefGoogle Scholar
  37. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17(12 Pt 2):1949–53.PubMedCrossRefGoogle Scholar
  38. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112(1):83–90.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Mohrschladt MF, Weverling-Rijnsburger AW, de Man FH, Stoeken DJ, Sturk A, Smelt AH, et al. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis. 2000;148(2):413–9.PubMedCrossRefGoogle Scholar
  40. Molenaar EA, Hwang SJ, Vasan RS, Grobbee DE, Meigs JB, D’Agostino RB Sr, et al. Burden and rates of treatment and control of cardiovascular disease risk factors in obesity: the Framingham heart study. Diabetes Care. 2008;31(7):1367–72.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Nagarajan V, Kohan L, Holland E, Keeley EC, Mazimba S. Obesity paradox in heart failure: a heavy matter. ESC Heart Fail. 2016;3(4):227–34.PubMedPubMedCentralCrossRefGoogle Scholar
  43. O’Brien KD, Chait A. Serum amyloid a: the “other” inflammatory protein. Curr Atheroscler Rep. 2006;8(1):62–8.PubMedCrossRefGoogle Scholar
  44. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett. 2007;581(26):5029–33.PubMedCrossRefGoogle Scholar
  45. O’Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature. 2009;462(7271):307–14.PubMedCrossRefGoogle Scholar
  46. Pan X, Hussain MM. Gut triglyceride production. Biochim Biophys Acta. 2012;1821(5):727–35.PubMedCrossRefGoogle Scholar
  47. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983–8.PubMedCrossRefGoogle Scholar
  48. Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich V, et al. Serum amyloid a: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia. 2005;48(3):519–28.PubMedCrossRefGoogle Scholar
  49. Qin B, Anderson RA, Adeli K. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1120–9.PubMedCrossRefGoogle Scholar
  50. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Insulin and hypertension. Relationship to obesity and glucose intolerance in pima Indians. Diabetes. 1990;39(11):1430–5.PubMedCrossRefGoogle Scholar
  51. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res. 1996;19(1):1–8.PubMedCrossRefGoogle Scholar
  52. Schubring C, Prohaska F, Prohaska A, Englaro P, Blum W, Siebler T, et al. Leptin concentrations in maternal serum and amniotic fluid during the second trimenon: differential relation to fetal gender and maternal morphometry. Eur J Obstet Gynecol Reprod Biol. 1999;86(2):151–7.PubMedCrossRefGoogle Scholar
  53. Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal-medial thickness. J Pediatr. 2005;147(5):651–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular alpha-adrenergic sensitivity. Hypertension. 1995;25(4 Pt 2):774–8.PubMedCrossRefGoogle Scholar
  55. Sutton GM, Trevaskis JL, Hulver MW, McMillan RP, Markward NJ, Babin MJ, et al. Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or −4 receptors. Endocrinology. 2006;147(5):2183–96.PubMedPubMedCentralCrossRefGoogle Scholar
  56. Taddei S, Virdis A, Mattei P, Favilla S, Salvetti A. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension. 1995;25(4 Pt 1):595–601.PubMedCrossRefGoogle Scholar
  57. Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol Endocrinol Metab. 2009;296(6):E1195–209.PubMedPubMedCentralCrossRefGoogle Scholar
  58. van Exel E, Gussekloo J, de Craen AJ, Frolich M. Bootsma-van Der Wiel a, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-plus study. Diabetes. 2002;51(4):1088–92.PubMedCrossRefGoogle Scholar
  59. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Vasilios Kotsis
    • 1
    Email author
  • Christina Antza
    • 1
  • Giannis Doundoulakis
    • 1
  • Stella Stabouli
    • 1
  1. 1.Aristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations